A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Unresectable or Metastatic Digestive System Malignancies (Colorectal and Gastric Cancer)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Izalontamab (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 02 Mar 2023 Status changed from recruiting to discontinued. Company research strategy adjustment.
- 16 Dec 2021 Status changed from not yet recruiting to recruiting.
- 14 Sep 2021 New trial record